리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2025년 05월
페이지 정보:영문 463 Pages
라이선스 & 가격 (부가세 별도)
한글목차
세계의 전립선 건강 시장은 2030년까지 512억 달러에 달할 전망
2024년에 338억 달러로 추정되는 세계의 전립선 건강 시장은 2024-2030년에 CAGR 7.2%로 성장하며, 2030년에는 512억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 전립선염 질환은 CAGR 5.7%를 기록하며, 분석 기간 종료시에는 274억 달러에 달할 것으로 예측됩니다. 양성 전립선 비대증형 부문의 성장률은 분석 기간에 CAGR 9.4%로 추정됩니다.
미국 시장은 92억 달러로 추정, 중국은 CAGR 11.0%로 성장 예측
미국의 전립선 건강 시장은 2024년에 92억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 106억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년의 CAGR은 11.0%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.7%와 6.8%로 예측됩니다. 유럽에서는 독일이 CAGR 4.7%로 성장할 것으로 예측됩니다.
세계의 "전립선 건강" 시장 - 왜 프로액티브 케어가 세계의 맨즈 헬스에 있어서 필수가 되고 있는가?
고령화로 인해 전립선 건강의 필요성이 높아지고 있다?
전립선 건강은 남성 인구의 급속한 고령화와 비뇨기 질환에 대한 인식이 높아짐에 따라 전 세계 의료 시스템의 핵심 관심사가 되고 있습니다. 전립선비대증(BPH), 전립선염, 전립선암과 같은 전립선 관련 질환은 50세 이상 남성들 사이에서 점점 더 많이 발생하고 있으며, 예방, 진단 및 치료 솔루션에 대한 수요가 꾸준히 증가하고 있습니다. 공중보건 캠페인과 검진 프로토콜의 강화는 조기 발견으로 이어져 예후를 개선하고 치료 기간을 연장하는 데 기여하고 있습니다. 또한 비만, 흡연, 좌식생활 등 생활습관 관련 위험요인이 젊은 연령층에서도 전립선 질환의 발병률을 악화시키고 있으며, PSA 검사, MRI, 경직장 초음파 검사 등 진단 툴의 발달로 전립선 건강 모니터링이 더욱 간편하고 정확하게 이루어지고 있습니다. 특히 북미, 유럽, 아시아 일부 지역에서는 정부와 의료 기관이 남성의 정기 건강검진에 전립선 검진을 포함시키면서 임상적 개입에 대한 인식과 수요가 더욱 높아지고 있습니다.
진단과 치료의 혁신이 임상 결과를 향상시키고 있는가?
전립선 건강 시장은 진단 및 치료 기술의 발전으로 큰 혜택을 누리고 있습니다. 레이저 치료, TURP(경요도적 전립선 절제술), 최신 로봇 보조 수술과 같은 최소침습 수술 기술은 회복 시간을 단축하고 환자의 삶의 질을 향상시키고 있습니다. 약리학적인 혁신도 중요한 역할을 하고 있습니다. 새로운 세대의 알파 차단제, 5알파 환원효소 억제제, 호르몬 요법은 부작용을 줄이면서 보다 효과적인 증상 관리를 제공합니다. 영상 진단에서는 다중 파라미터 MRI와 바이오마커 기반 검사를 통해 양성 질환과 악성 종양을 더 빠르고 정확하게 구별할 수 있게 되어 정확도가 높아지고 있습니다. 또한 면역요법 및 방사성 의약품 연구는 진행성 전립선암 치료에 유망한 치료법으로 떠오르고 있습니다. 원격 비뇨기과 플랫폼 및 모바일 건강 앱과 같은 디지털 건강 툴은 환자의 순응도, 증상 추적 및 가상 상담을 지원하고 있습니다. 진단과 치료가 더욱 통합됨에 따라 전체적인 치료 경로가 등장하고 임상 워크플로우와 환자 결과가 개선되고 있습니다.
남성의 건강 의식과 소비 행동이 수요를 견인?
남성 건강에 대한 사회적 인식의 변화는 전립선 건강의 상황을 변화시키고 있습니다. 과거에는 낙인과 경시 때문에 과소 진단되었던 전립선 질환은 유명인, 의학계, 디지털 인플루언서들의 옹호로 인해 주목받고 있습니다. 젊은 세대는 예방의학에 적극적이며, 정기 검진 및 유전자 검사에 참여하고 있습니다. 소비자 직접 판매 건강 플랫폼과 가정용 검사 키트는 남성에게 헬스케어의 자율성을 부여하고, 약국 및 1차 진료소는 전립선 전문 서비스를 더 쉽게 이용할 수 있도록 돕고 있습니다. 성 건강과 삶의 질에 대한 관심이 높아지면서 BPH나 발기부전 등 전립선 건강과 상호 연관된 질환을 조기에 치료받으려는 환자들이 늘고 있습니다. 남성들은 요실금이나 암과 같은 전립선 질환의 장기적인 영향에 대한 지식이 높아지면서 프리미엄 진단, 세컨드 오피니언, 지속적인 치료 요법에 대한 투자에 대한 의지가 높아지고 있습니다. 이러한 행동의 변화로 인해 시장은 소극적 치료에서 보다 예방적이고 개별화된 환자 중심적인 모델로 점차 전환되고 있습니다.
전립선 건강 시장의 성장은 몇 가지 요인에 의해 초래됩니다.
전립선 건강 시장의 성장은 인구 동향, 진화하는 진단 방법, 소비자 행동의 변화와 관련된 여러 요인에 의해 주도되고 있습니다. 최소침습적 시술, 바이오마커 검사, 영상 진단 방법의 기술적 발전으로 인해 조기 진단과 맞춤형 개입이 가능해졌습니다. 최종 용도 측면에서는 비뇨기과 클리닉, 전문 병원, 외래환자 센터의 환자 수가 증가하면서 특히 고령화 사회에서 종합적인 검진 및 치료 서비스에 대한 수요가 증가하고 있습니다. 소비자 선호도도 진화하고 있으며, 원격의료, 맞춤형 의료, 재택 검사 솔루션에 대한 수용이 확대되면서 의료 서비스 제공 및 소비 방식에 영향을 미치고 있습니다. 특히 신흥 시장의 의료 인프라 확충은 전립선 건강 서비스에 대한 광범위한 접근을 가능하게 하고 있습니다. 또한 전립선 관련 질환에 대한 의약품 파이프라인은 탄탄하며, 새로운 호르몬 요법 및 병용 요법에 초점을 맞춘 많은 임상시험이 진행되고 있습니다. 의료 기술 혁신, 환자 인식, 제도적 지원이 교차하면서 전립선 건강 시장이 전 세계에서 지속적으로 성장할 수 있는 비옥한 환경이 조성되고 있습니다.
Global Industry Analysts는 본사의 국가, 제조거점, 수출입(완제품 및 OEM)을 기반으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 인위적인 수입원가 증가, 수익성 감소, 공급망 재편 등 미시적 및 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.
Global Industry Analysts는 세계 주요 수석 이코노미스트(1,4,949명), 싱크탱크(62개 기관), 무역 및 산업 단체(171개 기관)의 전문가들의 의견을 면밀히 검토하여 생태계에 미치는 영향을 평가하고 새로운 시장 현실에 대응하고 있습니다. 모든 주요 국가의 전문가와 경제학자들이 관세와 그것이 자국에 미치는 영향에 대한 의견을 추적 조사했습니다.
Global Industry Analysts는 이러한 혼란이 향후 2-3개월 내에 마무리되고 새로운 세계 질서가 보다 명확하게 확립될 것으로 예상하고 있으며, Global Industry Analysts는 이러한 상황을 실시간으로 추적하고 있습니다.
2025년 4월: 협상 단계
이번 4월 보고서에서는 관세가 세계 시장 전체에 미치는 영향과 지역별 시장 조정에 대해 소개합니다. 당사의 예측은 과거 데이터와 진화하는 시장 영향요인을 기반으로 합니다.
2025년 7월: 최종 관세 재설정
고객님들께는 각 국가별 최종 리셋이 발표된 후 7월에 무료 업데이트 버전을 제공해 드립니다. 최종 업데이트 버전에는 명확하게 정의된 관세 영향 분석이 포함되어 있습니다.
상호 및 양자 간 무역과 관세의 영향 분석 :
미국 <>중국 <>멕시코 <>캐나다 <>EU <>일본 <>인도 <>기타 176개국
업계 최고의 이코노미스트: Global Industry Analysts의 지식 기반은 국가, 싱크탱크, 무역 및 산업 단체, 대기업, 그리고 세계 계량 경제 상황의 전례 없는 패러다임 전환의 영향을 공유하는 분야별 전문가 등 가장 영향력 있는 수석 이코노미스트 그룹을 포함한 14,949명의 이코노미스트를 추적하고 있습니다. 16,491개 이상의 보고서 대부분에 마일스톤에 기반한 2단계 출시 일정이 적용되어 있습니다.
목차
제1장 조사 방법
제2장 개요
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
스페인
러시아
기타 유럽
아시아태평양
호주
인도
한국
기타 아시아태평양
라틴아메리카
아르헨티나
브라질
멕시코
기타 라틴아메리카
중동
이란
이스라엘
사우디아라비아
아랍에미리트
기타 중동
아프리카
제4장 경쟁
KSA
영문 목차
영문목차
Global Prostate Health Market to Reach US$51.2 Billion by 2030
The global market for Prostate Health estimated at US$33.8 Billion in the year 2024, is expected to reach US$51.2 Billion by 2030, growing at a CAGR of 7.2% over the analysis period 2024-2030. Prostatitis Disease, one of the segments analyzed in the report, is expected to record a 5.7% CAGR and reach US$27.4 Billion by the end of the analysis period. Growth in the Benign Prostatic Hyperplasia Type segment is estimated at 9.4% CAGR over the analysis period.
The U.S. Market is Estimated at US$9.2 Billion While China is Forecast to Grow at 11.0% CAGR
The Prostate Health market in the U.S. is estimated at US$9.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.6 Billion by the year 2030 trailing a CAGR of 11.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.7% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.7% CAGR.
Global "Prostate Health" Market - Why Is Proactive Care Becoming a Global Men’s Health Imperative?
Is the Aging Population Raising the Urgency Around Prostate Health?
Prostate health is becoming a central concern in global healthcare systems, largely due to the rapid aging of the male population and increased awareness around urological conditions. Prostate-related disorders such as benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer are increasingly prevalent among men aged 50 and above, creating steady demand for preventive, diagnostic, and therapeutic solutions. Public health campaigns and enhanced screening protocols have led to early detection, contributing to better prognosis and a wider treatment window. Additionally, lifestyle-related risk factors-such as obesity, smoking, and sedentary habits-are exacerbating the incidence of prostate issues, even in younger age groups. The expansion of diagnostic tools like PSA testing, MRI, and transrectal ultrasound is making prostate health monitoring more accessible and precise. Governments and health organizations are integrating prostate care into regular male health checkups, particularly in North America, Europe, and parts of Asia, further boosting awareness and demand for clinical interventions.
Are Innovations in Diagnosis and Treatment Enhancing Clinical Outcomes?
The prostate health market is benefiting significantly from advancements in diagnostic and therapeutic technologies. Minimally invasive surgical techniques, such as laser therapy, TURP (transurethral resection of the prostate), and newer robotic-assisted procedures, are reducing recovery time and improving quality of life for patients. Pharmacological innovation is also playing a key role; newer generations of alpha-blockers, 5-alpha reductase inhibitors, and hormone therapies are offering more targeted symptom management with fewer side effects. Diagnostic imaging is becoming more precise with multiparametric MRI and biomarker-based tests allowing earlier and more accurate differentiation between benign conditions and malignancies. Furthermore, research into immunotherapy and radiopharmaceuticals is showing promise in treating advanced-stage prostate cancer. Digital health tools, such as tele-urology platforms and mobile health apps, are supporting patient compliance, symptom tracking, and virtual consultations. As diagnostics and therapeutics become more integrated, holistic care pathways are emerging, improving clinical workflows and patient outcomes.
Is Male Health Awareness and Consumer Behavior Driving Demand?
Societal shifts in how men approach their health are transforming the prostate health landscape. Traditionally underdiagnosed due to stigma and neglect, prostate conditions are now receiving increased attention thanks to advocacy from celebrities, medical societies, and digital influencers. Younger generations are more proactive about preventive care, participating in regular checkups and genetic screenings. Direct-to-consumer health platforms and home testing kits are giving men more autonomy in managing their health, while pharmacies and primary care clinics offer greater accessibility to prostate-specific services. The growing emphasis on sexual wellness and quality of life is also pushing patients to seek early treatment for conditions like BPH and erectile dysfunction, which are often interlinked with prostate health. Men are becoming more educated on the long-term implications of prostate disease, such as incontinence or cancer, and are therefore more willing to invest in premium diagnostics, second opinions, and ongoing care regimens. These behavioral trends are gradually shifting the market from reactive treatment toward a more preventive, personalized, and patient-centric model.
The Growth in the Prostate Health Market Is Driven by Several Factors…
The growth in the prostate health market is driven by several factors related to demographic trends, evolving diagnostics, and shifting consumer behavior. Technological advancements in minimally invasive procedures, biomarker testing, and imaging modalities are allowing for earlier diagnosis and tailored interventions. From an end-use perspective, the rising patient volumes in urology clinics, specialty hospitals, and outpatient centers-especially in aging economies-are pushing demand for comprehensive screening and treatment services. Consumer preferences are also evolving, with increased acceptance of telehealth, personalized medicine, and at-home testing solutions influencing how care is delivered and consumed. Healthcare infrastructure expansion, particularly in emerging markets, is enabling broader access to prostate health services. Moreover, the pharmaceutical pipeline for prostate-related conditions is robust, with numerous clinical trials focused on novel hormonal therapies and combination regimens. The intersection of medical innovation, patient awareness, and systemic support is creating a fertile environment for the sustained growth of the prostate health market globally.
SCOPE OF STUDY:
The report analyzes the Prostate Health market in terms of units by the following Segments, and Geographic Regions/Countries:
Segments:
Disease Type (Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type, Prostate Cancer Disease Type); Treatment (Chemotherapy Treatment, Hormone Therapy Treatment, Immunotherapy Treatment); Administration Route (Oral Route, Parenteral Route); Distribution Channel (Hospital Pharmacies Distribution Channel, Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel)
Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.
Select Competitors (Total 37 Featured) -
Abbott Laboratories
Amgen Inc.
Astellas Pharma Inc.
AstraZeneca PLC
Bayer AG
Bristol-Myers Squibb Company
Clovis Oncology, Inc.
Eli Lilly and Company
Endo Pharmaceuticals Inc.
Ferring Pharmaceuticals Inc.
GlaxoSmithKline plc
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.
ProArc Medical Ltd.
Quibim
Sanofi
Siemens Healthineers AG
Veru Inc.
TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.
We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.
We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.
As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.
To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!
APRIL 2025: NEGOTIATION PHASE
Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.
JULY 2025 FINAL TARIFF RESET
Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.
Reciprocal and Bilateral Trade & Tariff Impact Analyses:
USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.
Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.
COMPLIMENTARY PREVIEW
Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Impact of Covid-19 and a Looming Global Recession
Prostate Health - Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Geriatric Population and Life Expectancy Drive Growth in Prostate Care Services
Increased Screening Awareness for Prostate Cancer Spurs Preventive Diagnosis Uptake
Technological Advancements in Imaging and Biopsy Tools Improve Diagnostic Accuracy
Minimally Invasive Surgery Techniques Propel Growth in Robotic-Assisted Treatments
Expansion of Telehealth Platforms Facilitates Access to Urologists and Treatment Continuity
Availability of Targeted Drug Therapies Improves Management of Advanced Prostate Conditions
Development of AI-Driven Diagnostics Tools Enhances Precision in Prostate Disease Detection
Public-Private Health Campaigns Promote Early Detection and Routine PSA Testing
Shift Toward Outpatient and Ambulatory Surgical Centers Expands Treatment Accessibility
Rising Male Health Awareness Initiatives Normalize Prostate Screenings Among Younger Demographics
Adoption of MRI-Ultrasound Fusion Systems Strengthens Clinical Decision-Making
Pharma R&D Pipelines Focus on Next-Generation Hormone Therapies for Prostate Cancer
Insurance Coverage Expansion in Key Markets Increases Treatment Affordability
Integration of Genomic Testing in Prostate Cancer Risk Assessment Creates Tailored Treatment Paths
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Prostate Health Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Prostate Health by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 4: World 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Prostatitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Prostatitis Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 7: World 15-Year Perspective for Prostatitis Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Benign Prostatic Hyperplasia Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Benign Prostatic Hyperplasia Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 10: World 15-Year Perspective for Benign Prostatic Hyperplasia Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Prostate Cancer Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Prostate Cancer Disease Type by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 13: World 15-Year Perspective for Prostate Cancer Disease Type by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Retail Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 16: World 15-Year Perspective for Retail Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Online Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 19: World 15-Year Perspective for Online Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Hospital Pharmacies Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 22: World 15-Year Perspective for Hospital Pharmacies Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Chemotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 25: World 15-Year Perspective for Chemotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Hormone Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Hormone Therapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 28: World 15-Year Perspective for Hormone Therapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Immunotherapy Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 31: World 15-Year Perspective for Immunotherapy Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 34: World 15-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Parenteral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 37: World 15-Year Perspective for Parenteral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 38: USA Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: USA Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 40: USA 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 41: USA Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 42: USA Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 43: USA 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 44: USA Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 46: USA 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 49: USA 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
CANADA
TABLE 50: Canada Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: Canada Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 52: Canada 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 53: Canada Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 54: Canada Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 55: Canada 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 56: Canada Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 58: Canada 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 61: Canada 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
JAPAN
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 62: Japan Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Japan Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 64: Japan 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 65: Japan Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 66: Japan Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 67: Japan 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 68: Japan Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 70: Japan 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 73: Japan 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
CHINA
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 74: China Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: China Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 76: China 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 77: China Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 78: China Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 79: China 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 80: China Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 82: China 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 85: China 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
EUROPE
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 86: Europe Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 87: Europe Historic Review for Prostate Health by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 88: Europe 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
TABLE 89: Europe Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 90: Europe Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 91: Europe 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 92: Europe Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 94: Europe 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 97: Europe 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 100: Europe 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
FRANCE
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 101: France Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 102: France Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 103: France 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 104: France Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 105: France Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 106: France 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 107: France Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 108: France Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 109: France 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 110: France Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 112: France 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
GERMANY
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 113: Germany Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 114: Germany Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 115: Germany 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 116: Germany Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 117: Germany Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 118: Germany 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 119: Germany Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 120: Germany Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 121: Germany 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 122: Germany Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 124: Germany 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
ITALY
TABLE 125: Italy Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 126: Italy Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 127: Italy 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 128: Italy Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 129: Italy Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 130: Italy 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 131: Italy Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 132: Italy Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 133: Italy 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 134: Italy Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 136: Italy 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
UNITED KINGDOM
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 137: UK Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 138: UK Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 139: UK 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 140: UK Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 141: UK Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 142: UK 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 143: UK Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 144: UK Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 145: UK 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 146: UK Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 148: UK 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
SPAIN
TABLE 149: Spain Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 150: Spain Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 151: Spain 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 152: Spain Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 153: Spain Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 154: Spain 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 155: Spain Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 156: Spain Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 157: Spain 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 158: Spain Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 159: Spain Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 160: Spain 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
RUSSIA
TABLE 161: Russia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 162: Russia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 163: Russia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 164: Russia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 165: Russia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 166: Russia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 167: Russia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 168: Russia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 169: Russia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 170: Russia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 171: Russia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 172: Russia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
REST OF EUROPE
TABLE 173: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 174: Rest of Europe Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 175: Rest of Europe 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 176: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 177: Rest of Europe Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 178: Rest of Europe 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Europe Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 181: Rest of Europe 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Europe Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 184: Rest of Europe 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
ASIA-PACIFIC
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 185: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 186: Asia-Pacific Historic Review for Prostate Health by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 187: Asia-Pacific 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
TABLE 188: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 189: Asia-Pacific Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 190: Asia-Pacific 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 192: Asia-Pacific Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 193: Asia-Pacific 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 195: Asia-Pacific Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 196: Asia-Pacific 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 198: Asia-Pacific Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 199: Asia-Pacific 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
AUSTRALIA
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 200: Australia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 201: Australia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 202: Australia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 203: Australia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 204: Australia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 205: Australia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 206: Australia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 207: Australia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 208: Australia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 209: Australia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 210: Australia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 211: Australia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
INDIA
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 212: India Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 213: India Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 214: India 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 215: India Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 216: India Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 217: India 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 218: India Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 219: India Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 220: India 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 221: India Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 222: India Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 223: India 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
SOUTH KOREA
TABLE 224: South Korea Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 225: South Korea Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 226: South Korea 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 227: South Korea Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 228: South Korea Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 229: South Korea 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 230: South Korea Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 231: South Korea Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 232: South Korea 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 233: South Korea Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 234: South Korea Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 235: South Korea 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 236: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 237: Rest of Asia-Pacific Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 238: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 239: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 240: Rest of Asia-Pacific Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 241: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Asia-Pacific Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 244: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Asia-Pacific Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 247: Rest of Asia-Pacific 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
LATIN AMERICA
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 248: Latin America Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 249: Latin America Historic Review for Prostate Health by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 250: Latin America 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
TABLE 251: Latin America Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 252: Latin America Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 253: Latin America 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 254: Latin America Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 255: Latin America Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 256: Latin America 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 257: Latin America Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 258: Latin America Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 259: Latin America 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 260: Latin America Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 261: Latin America Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 262: Latin America 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
ARGENTINA
TABLE 263: Argentina Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 264: Argentina Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 265: Argentina 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 266: Argentina Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 267: Argentina Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 268: Argentina 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 269: Argentina Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 270: Argentina Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 271: Argentina 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 272: Argentina Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 273: Argentina Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 274: Argentina 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
BRAZIL
TABLE 275: Brazil Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 276: Brazil Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 277: Brazil 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 278: Brazil Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 279: Brazil Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 280: Brazil 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 281: Brazil Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 282: Brazil Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 283: Brazil 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 284: Brazil Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 285: Brazil Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 286: Brazil 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
MEXICO
TABLE 287: Mexico Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 288: Mexico Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 289: Mexico 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 290: Mexico Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 291: Mexico Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 292: Mexico 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 293: Mexico Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 294: Mexico Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 295: Mexico 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 296: Mexico Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 297: Mexico Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 298: Mexico 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
REST OF LATIN AMERICA
TABLE 299: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 300: Rest of Latin America Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 301: Rest of Latin America 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 302: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 303: Rest of Latin America Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 304: Rest of Latin America 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Latin America Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 307: Rest of Latin America 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Latin America Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 310: Rest of Latin America 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
MIDDLE EAST
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 311: Middle East Recent Past, Current & Future Analysis for Prostate Health by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 312: Middle East Historic Review for Prostate Health by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 313: Middle East 15-Year Perspective for Prostate Health by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
TABLE 314: Middle East Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 315: Middle East Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 316: Middle East 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 317: Middle East Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 318: Middle East Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 319: Middle East 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 320: Middle East Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 321: Middle East Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 322: Middle East 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 323: Middle East Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 324: Middle East Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 325: Middle East 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
IRAN
TABLE 326: Iran Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 327: Iran Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 328: Iran 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 329: Iran Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 330: Iran Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 331: Iran 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 332: Iran Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 333: Iran Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 334: Iran 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 335: Iran Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 336: Iran Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 337: Iran 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
ISRAEL
TABLE 338: Israel Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 339: Israel Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 340: Israel 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 341: Israel Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 342: Israel Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 343: Israel 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 344: Israel Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 345: Israel Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 346: Israel 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 347: Israel Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 348: Israel Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 349: Israel 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
SAUDI ARABIA
TABLE 350: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 351: Saudi Arabia Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 352: Saudi Arabia 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 353: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 354: Saudi Arabia Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 355: Saudi Arabia 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 357: Saudi Arabia Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 358: Saudi Arabia 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 360: Saudi Arabia Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 361: Saudi Arabia 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 362: UAE Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 363: UAE Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 364: UAE 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 365: UAE Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 366: UAE Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 367: UAE 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 368: UAE Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 369: UAE Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 370: UAE 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 371: UAE Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 372: UAE Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 373: UAE 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
REST OF MIDDLE EAST
TABLE 374: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 375: Rest of Middle East Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 376: Rest of Middle East 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 377: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 378: Rest of Middle East Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 379: Rest of Middle East 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 381: Rest of Middle East Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 382: Rest of Middle East 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 384: Rest of Middle East Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 385: Rest of Middle East 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030
AFRICA
Prostate Health Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 386: Africa Recent Past, Current & Future Analysis for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 387: Africa Historic Review for Prostate Health by Disease Type - Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 388: Africa 15-Year Perspective for Prostate Health by Disease Type - Percentage Breakdown of Value Sales for Prostatitis Disease Type, Benign Prostatic Hyperplasia Disease Type and Prostate Cancer Disease Type for the Years 2015, 2025 & 2030
TABLE 389: Africa Recent Past, Current & Future Analysis for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 390: Africa Historic Review for Prostate Health by Distribution Channel - Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 391: Africa 15-Year Perspective for Prostate Health by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacies Distribution Channel, Online Pharmacies Distribution Channel and Hospital Pharmacies Distribution Channel for the Years 2015, 2025 & 2030
TABLE 392: Africa Recent Past, Current & Future Analysis for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 393: Africa Historic Review for Prostate Health by Treatment - Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 394: Africa 15-Year Perspective for Prostate Health by Treatment - Percentage Breakdown of Value Sales for Chemotherapy Treatment, Hormone Therapy Treatment and Immunotherapy Treatment for the Years 2015, 2025 & 2030
TABLE 395: Africa Recent Past, Current & Future Analysis for Prostate Health by Administration Route - Oral Route and Parenteral Route - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 396: Africa Historic Review for Prostate Health by Administration Route - Oral Route and Parenteral Route Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
TABLE 397: Africa 15-Year Perspective for Prostate Health by Administration Route - Percentage Breakdown of Value Sales for Oral Route and Parenteral Route for the Years 2015, 2025 & 2030